CSL Behring receives FDA approval to treat haemophilia A

CSL Behring has received approval from the US Food and Drug Administration (FDA) for the use of its recombinant factor VIII single-chain therapy, Afstyla, as a treatment for haemophilia A.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news